Wikipedia

User:BD2412/sandbox/archive/78

< User:BD2412‎ | sandbox‎ | archive
Alex Zhavoronkov
Born
Riga, Latvia[1][2]
Alma materQueen's University at Kingston
Johns Hopkins University (JHU)[3]
Known forThe Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy
Scientific career
Fieldsaging, regenerative medicine, drug development, artificial intelligence
InstitutionsInsilico Medicine, Biogerontology Research Foundation

New text:

edit

Alex Zhavoronkov (born Aleksandrs Zavoronkovs)[3] is a Latvian-born scientist and author working in biotechnology, regenerative medicine, and aging economics. He is the founder and CEO of Insilico Medicine,[4][5] and as of 2024, was also the director of the Biogerontology Research Foundation,[6][7] a UK-based think-tank for aging research. Zhavoronkov has published a substantial number of papers, and books including The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy.

Early life and education

edit

Born in Latvia,[1][2][8] Zhavoronkov received two bachelor's degrees from Queen's University,[3] a master's degree in biotechnology from Johns Hopkins University,[8] and a PhD in physics and mathematics from Moscow State University.[3] In the mid 2010s, he was an adjunct professor at the Moscow Institute of Physics and Technology.[9] As of 2024, he was an adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.[10]

In 2014, Zhavoronkov began work towards using "massive data sets and Al to significantly speed up the drug discovery process",[11] and established Insilico at Johns Hopkins University in Baltimore.[8][11] Tony Robbins and Peter Diamandis were early investors in Zhavoronkov's efforts.[11]

In 2016, Zhavoronkov was the chief science officer for Beauty.AI, an artificial intelligence technology that evaluate people's external appearance through certain algorithms. In this role, he responded to concerns about ethnic bias in results generated by the platform by attributing them to a lack of data provided to it.[12][13]

In 2022, Zhavoronkov was an author of one of the first peer-reviewed published papers to formally credit ChatGPT as a coauthor.[14] Zhavoronkov reported that when he asked ChatGPT itself whether it should be named as a coauthor, "it responded with multiple compelling reasons as to why it should not".[14]

In February 2023, Wesley J. Smith, writing for National Review, sharply criticized comments by Zhavoronkov, who had observed that organ transplants used to facilitate life extension could someday be provided by using human clones generated without cognitive functions.[15]

Potential source integration

edit

"'It is the first fully generative AI drug to reach human clinical trials, and specifically Phase II trials with patients', Alex Zhavoronkov, founder and CEO of Insilico Medicine, told CNBC".[16]

"Insilico... founder and CEO Alex Zhavoronkov".[8]

"Researchers had been using GANs to do things like design new objects or create one-of-a-kind, fake human faces, but Zhavoronkov wanted to apply them to pharmacology".[11]

"The video project was bankrolled in part by Alex Zhavoronkov, the founder of Insilico Medicine, a large AI drug discovery company, who is also a prominent figure in anti-aging research. After Zhavoronkov posted the video on his LinkedIn account, commenters noticed that it is his face on the two bodies shown in the video". 'I can confirm I helped design and fund a few things', Zhavoronkov told MIT Technology Review in a WhatsApp message, in which he also claimed that 'some important and famous people are supporting [it] financially'".[17]

Previous text:

edit

Director of the International Aging Research Portfolio, an open-access repository of biomedical grants.

Career

Zhavoronkov is the co-founder and CEO of Insilico Medicine, a Hong Kong-based deep learning company focused on drug discovery[18][19] and biomarker development for aging and aging-associated diseases.[20][21]

AI writer Calum Chace wrote that "[w]ithin the longevity research community, Alex Zhavoronkov is well-known for his relentless focus. He works seven days a week and takes no holidays".[1] In 2022, Zhavoronkov participated in a round of financing for Insilico Medicine that raised $60 million for the venture.[22] Zhavoronkov asserted at the time that the industry was "in 'biotechnology winter' where many companies are running out of cash and are dying", and that his fundraising was positioning the company for a coming "biotech spring".[22] In 2023, Zhavoronkov stated that he had "moved the company's R&D to China to capitalize on 'half a trillion dollars' worth of infrastructure and hundreds of thousands of scientists to enable AI-designed drugs".[7]

Publications

edit

Since 2010, Zhavoronkov has authored or co-authored over 250 scientific articles published in refereed journals and referenced in PubMed.[23][24]

In November 2017, Zhavoronkov proposed the application of the deep learning techniques and blockchain technology for managing human life data.[25][26][27]

Books
  • Moskalev, Alexey; Stambler, Ilia; Zhavoronkov, Alex (2023), Artificial Intelligence for Healthy Longevity, Springer, ASIN B0C6CS2XJ3
  • Zhavoronkov, Alex (2013). The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy. Macmillan. ISBN 978-0230342200.[19][28][29][30][31]
  • Zhavoronkov, Alex (2012), Dating A.I.: A guide to falling in love with Artificial Intelligence, RE/Search Publications, ISBN 978-1889307350
Articles
Patents
  • US patent 8442626B2, Alex Zavoronkov, Mikhail Bakhnyan, "Systems and methods for communicating with a computer using brain activity patterns", issued May 14, 2013 [32]

References

edit
  1. ^ a b c Chace, Calum (November 9, 2022). "How Insilico Medicine Uses AI To Accelerate Drug Development". Forbes Magazine.
  2. ^ a b Smyth, Jamie (June 26, 2023). "Biotech begins human trials of drug designed by artificial intelligence". Financial Times.
  3. ^ a b c d "Alex Zhavoronkov Aims to Take Over the Drug Development World with AI". Genetic Engineering and Biotechnology News. June 20, 2023.
  4. ^ Eric Smaley (2017). "AI-powered drug discovery captures pharma interest". Nature Biotechnology. 35 (7): 605. doi:10.1038/nbt0717-604. PMID 28700560. S2CID 205269847.
  5. ^ Tan, Dawn; Baker, Jalelah Abu (January 4, 2023). "Big investors pour funds into longevity research, accelerating growth in field". CNA.
  6. ^ "Biogerontology Research Foundation Salutes Staff On Multi-Year Drug Development Agreement". Bioengineer.org. August 14, 2017. Retrieved 28 November 2017.
  7. ^ a b Raiany Romanni, "Want to live to 150? The world needs more humans", The Boston Globe (April 2, 2023), p. K1, K5.
  8. ^ a b c d Matsuyama, Kanoko (November 14, 2023). "Race for first drug discovered by AI nears key milestone". The Japan Times.
  9. ^ "News: Neural network learns to select potential anticancer drugs". MIPT News. February 9, 2017.
  10. ^ "A rather disruptive bunch". Buck Institute for Research on Aging. Retrieved June 23, 2024.
  11. ^ a b c d Robbins, Tony; Diamandis, Peter H.; Hariri, Robert (2022). Life Force. Simon and Schuster. p. 556-57. ISBN 978-1982121709.
  12. ^ Pearson, Jordan (2016-09-05). "Why An AI-Judged Beauty Contest Picked Nearly All White Winners". Motherboard. Retrieved 2017-01-17.
  13. ^ Cite error: The named reference disruptive was invoked but never defined (see the help page).
  14. ^ a b Berenbaum, May R. (November 22, 2023). "Welcome, AI overlords?". Proceedings of the National Academy of Sciences of the United States of America (PNAS). Vol. 120, no. 48. doi:10.1073/pnas.2318980120.
  15. ^ Smith, Wesley J. (February 8, 2023). "Harvesting Clones to Live Forever Would Be Monstrous". National Review.
  16. ^ Field, Hayden (June 29, 2023). "The first fully A.I.-generated drug enters clinical trials in human patients". CNBC.
  17. ^ Regalado, Antonio (May 23, 2024). "That viral video showing a head transplant is a fake. But it might be real someday". MIT Technology Review.
  18. ^ Brazil, Rachel (7 December 2017). "Artificial Intelligence: will it change the way drugs are discovered?". Pharmaceutical Journal, the Journal of the Royal Pharmacological Society.
  19. ^ a b Tom Blackwell, "Cutting-edge science seeks treatment for age", Toronto National Post (February 6, 2021), p. As5.
  20. ^ Thomas, Uduak Grace (March 28, 2014). "GenomeWeb: In Silico Medicine Opens US Office, Prepares to Launch Drug Discovery Software for Aging Research Market" – via www.genomeweb.com.
  21. ^ Gantz, Sarah (February 23, 2017). "Insilico Medicine raises $10 million". The Baltimore Sun.
  22. ^ a b Liao, Rita (June 6, 2022). "Hong Kong's AI drug discovery firm Insilico closes $60M Series D". TechCrunch.
  23. ^ Alex Zhavoronkov Google Scholar page by Publication Date Google Scholar by Publication Date.
  24. ^ PubMed Bibliography Pubmed.
  25. ^ "Skolkovo scientist says AI and blockchain could accelerate biomedical research". old.sk.ru.
  26. ^ "Bitcoin Tech Lets People Reclaim Their Data, Says Medical Startup". Inverse. December 7, 2017.
  27. ^ Haskins, Caroline (December 6, 2017). "This Biotech Company Wants You to Give it Selfies and Blood Tests in Exchange for Cryptocurrency".
  28. ^ Scheffler, Daniel (July 9, 2013). "The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy (review)". Edge Media.
  29. ^ Bloomberg Businessweek, Critic 07.22.2013 pp. 74.
  30. ^ "CBS Radio with Dan Raviv in Washington, DC". September 9, 2013. Event occurs at 1:45–5:20.
  31. ^ "Interview with Aging Expert – Alex Zhavoronkov". Book Tour Radio. August 20, 2013.
  32. ^ Bobrov, P; Frolov, A; Cantor, C; Fedulova, I; Bakhnyan, M; Zhavoronkov, A (2011). "Brain-computer interface based on generation of visual images". PLOS ONE. 6 (6): e20674. Bibcode:2011PLoSO...620674B. doi:10.1371/journal.pone.0020674. PMC 3112189. PMID 21695206.
edit

Previously deleted text

edit
Alex Zhavoronkov
BornAugust 17, 1979 (age 38)
Riga, Latvia
Alma materJohns Hopkins University (JHU)
Known forThe Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy
Scientific career
Fieldsaging, regenerative medicine, drug development, artificial inteligence
InstitutionsInsilico Medicine, Biogerontology Research Foundation

Director of the International Aging Research Portfolio, an open-access repository of biomedical grants.

Career

edit

He is the co-founder and CEO of Insilico Medicine, a deep learning company focused on drug discovery[1] and biomarker development for aging and aging-associated diseases located at the Emerging Technology Centers of the Johns Hopkins University.[2][3]

Editorial roles and conferences

edit

Dr. Zhavoronkov is the editor of Aging[4] and associate editor of Frontiers in Genetics of Aging.[5] He co-founded the "Annual Aging Research for Drug Discovery Forum" in Basel, Switzerland in 2014, previously called the International Symposium on Geroprotectors [6] as part of the EMBO/Basel Life.[7]

References

edit
  1. ^ Artificial Intelligence: will it change the way drugs are discovered? Pharmaceutical Journal, The Journal of the Royal Pharmacological Society
  2. ^ GenomeWeb: In Silico Medicine Opens US Office, Prepares to Launch Drug Discovery Software for Aging Research Market by Uduak Grace Thomas, March 28, 2014
  3. ^ Baltimore Sun, Insilico Medicine raises $10 million, by Sarah Gantz, February 23, 2017
  4. ^ Aging Editorial Board
  5. ^ Frontiers in Genetics of Aging Editorial Board
  6. ^ New Scientist report from the International Symposium on Geroprotectors in Basel
  7. ^ 4th Annual Aging Research & Drug Discovery Forum in Basel, Switzerland
edit



Category:Living people Category:Johns Hopkins University alumni Category:Moscow State University alumni Category:Queen's University at Kingston alumni Category:Biogerontologists Category:Russian transhumanists

Retrieved from "https://en.wikipedia.org/w/index.php?title=User:BD2412/sandbox/archive/78&oldid=1230579749"